Current Gene Therapy

Ignacio Anegon
Director INSERM UMR 1064-Center for Research in Transplantation and Immunology
CHU de Nantes. 30, boulevard
Nantes
France

Back

Restoration of Transgene Expression in Hematopoietic Cells with Drug-Selectable Marker Genes

Author(s): Thomas Licht, Chrisitian Peschel.

Abstract:

Somatic gene therapy is supposed to cure life-threatening hema­to­poietic dis­­­orders but is limited by unstable trans­gene ex­pression. Efficient gene transfer to hematopoietic progenitor cells does not ensure long-term gene expression. It would therefore be advantageous if the expression of transgenes could be restored in bone marrow. Transfer of drug resistance genes such as the multidrug resistance (MDR1) or mutated dihydrofolate reductase (DHFR) genes to hematopoietic cells protects them from the toxicity of anticancer drugs. In addition, transduced cells obtain a selective growth advantage in the presence of anticancer drugs. This can be used to introduce and enrich otherwise non-selectable genes by cotransfer to target cells. Bicistronic vectors have been constructed for coexpression of drug resistance genes and non-selectable, therapeutic genes with the use of an internal ribosomal entry-site (IRES). With the use of bicistronic vectors, expression and function of therapeutic genes hav e been increased in tissue culture and in animal models. Further preclinical investigations are needed to identify optimal conditions for selection.

Keywords: Hematopoietic Cells, Transgene Expression

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 2
ISSUE: 2
Year: 2002
Page: [227 - 234]
Pages: 8
DOI: 10.2174/1566523024605636
Price: $58